Calithera Biosciences Gross Profit

Calithera Biosciences (CALA) currently reports a gross profit of $0 as of December 2022. That compares with $9.8M in the prior-year period — down 100.0% year over year. That is below the Healthcare sector average of $66B. Use the charts on this page to explore Calithera Biosciences's gross profit history and peer comparisons.

Calithera Biosciences's gross profit decreased from $9.8M to $0 — a 100.0% year-over-year decrease (period ending December 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Calithera Biosciences's gross profit of $0 is lower than the Healthcare sector average of $66B. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Calithera Biosciences reported $0 in gross profit as of December 2022. That compares with $9.8M in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current gross profit of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $66B. From there, open related valuation or income-statement pages for Calithera Biosciences, and consider following CALA for alerts when major investors trade the stock.